Læknablaðið - 15.07.2010, Blaðsíða 16

FRÆÐIGREINAR
RANNSÓKNIR
2. Beasley R, Keil U, von Mutius E, et al. Worldwide
variation in prevalence of symptoms of asthma, allergic
rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet 1998;
351:1225-32.
3. Neukirch F, Pin I, Knani J, et al. Prevalence of asthma and
asthma-like symptoms in three French cities. Respir Med
1995; 89: 685-92.
4. Haitchi HM, Holgate ST. New strategies in the treatment and
prevention of allergic diseases. Expert Opin Investig Drugs
2004; 13:107-24.
5. Rosenwasser LJ. Treatment of allergic rhinitis. Am J Med
2002; 113:17S-24S.
6. Larché M, Akdis CA, Valenta R. Immunological mechanisms
of allergen-specific immunotherapy. Nature Rev Immunol
2006; 6: 761-71.
7. Akdis M, Akdis CA. Mechanisms of allergen-specific
immunotherapy. J Allergy Clin Immunol 2007; 119: 780-9.
8. Adkinson NF Jr. Immunotherapy for allergic rhinitis. N Engl
J Med 1999; 341: 468-75.
9. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of
immunotherapy. J Allergy Clin Immunol 2004; 113:1025-34.
10. Jacobsen L, Niggemann B, Dreborg S, et al. Specific
immunotherapy has long-term preventive effect of seasonal
and perennial asthma: 10-Year follow-up on the PAT study.
Allergy 2007; 62: 943-8.
11. Vrtala S. From allergen genes to new forms of allergy
diagnosis and treatment. Allergy 2008; 63: 299-309.
12. Gíslason D, Guðmundsson G, Tómasson K, Sigurðarsson
SÞ, Hallas T. Maurar í húsryki á íslenskum bóndabæjum.
Læknablaðið 2008; 94: 723-7.
13. Malling HJ, Weeke B. Position paper of the European
Academy of Allergology and Clinical Immunology. Allergy
1993; 48: 9-35.
14. Pipet A, Botturi K, Pinot D, Vervloet D, Magnan A. Allergen-
specific immunotherapy in allergic rhinitis and asthma.
Mechanisms and proof of efficacy. Respir Med 2009; In Press.
15. Bousquet J, Hejjaoui A, Dhivert H, Clauzel AM, Michel
FB. Immunotherapy with a standardized Dermatophagoides
pteronyssinus extract. Systemic reactions during the rush
protocol in patients suffering from asthma. J Allergy Clin
Immunol 1989; 83: 797-802.
16. Lockey RF, Windom HH. An update on the safety of specific
immunotherapy. Curr Opin Allergy Clin Immunol 2008; 8:
571-6.
17. Jacobsen L, Núchel Petersen B, Jáwihl, Wenstein HL, Ipsen
H. Immunotherapy with partially purified and standardized
tree pollen extracts. IV. Results from long-term (6-year)
follow-up. Allergy 1997; 52: 914-20.
18. Eng PA, Borer-Reinhold M, Heijnen I, Gnehm HPE. Twelve-
year follow-up after discontinuation of preseasonal grass
pollen immunotherapy in childhood. Allergy 2006; 61: 198-
201.
19. Jacobsen L, Valovirta E. How strong is the evidence that
immunotherapy in children prevents the progression of
allergy and asthma? Curr Opin Allergy Clin Immunol 2007;
7: 556-60.
20. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A,
Durham S. Allergen injection immunotherapy for seasonal
allergic rhinitis. Cochrane Database Syst Rev 2007: 89.
21. Passalacqua G, Durham SR, Global Allergy A. Allergic
rhinitis and its impact on asthma update: Allergen
immunotherapy. J Allergy Clin Immunol 2007; 119: 881-91.
22. Johnstone DE, Dutton A. The value of hyposensitization
therapy for bronchial asthma in children - a 14-year study.
Pediatrics 1968; 42: 793-802.
23. Grembiale RD, Camporota L, Naty S, Tranfa CME, Djukanovic
R, Marsico SA. Effects of specific immunotherapy in allergic
rhinitic individuals with bronchial hyperresponsiveness. Am
J Respir Crit Care Med. 2000; 162: 2048-52.
24. Johnstone DE, Crump L. Value of hyposensitization therapy
for perennial bronchial asthma in children. Pediatrics 1961;
61: 39-44.
25. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani
S. Prevention of new sensitizations in asthmatic
children monosensitized to house dust mite by specific
immunotherapy. A six-year follow-up study. Clin Exp
Allergy 2001; 31:1392-7.
26. Purello-D'Ambrosio F, Gangemi S, Merendino RA, et al.
Prevention of new sensitizations in monosensitized subjects
submitted to specific immunotherapy or not. A retrospective
study. Clin Exp Allergy 2001; 31:1295-302.
27. Marogna M, Spadolini I, Massolo A, Canonica GW,
Passalacqua G. Randomized controlled open study of
sublingual immunotherapy for respiratory allergy in real-
life: clinical efficacy and more. Allergy 2004; 59:1205-10.
>•
DC
<
2
5
D
W
I
w
o
z
LU
Allergen immunotherapy in lceland 1977-2006
Introduction: The prevelance of allery and asthma
has increased rapidly over the last 3 decades and is
now estimated that 25-30% of population in Western
industrialized countries show symptoms of allergy or
asthma. The aim of this study was to reveal the success
of allergen immunotherapy (AIT) in Landspitali from 1977-
2006.
Material and methods: During the study period a total
number of 289 individuals underwent immunotherapy in
outpatient clinic of allergy and asthma in Landspítali. A
total number of 169 individuals were contacted, of whom
128 (76%) accepted to participate in the study. The
evaluation was based on medical records, standardized
questionnaire and skin-prick tests.
Results: Patients were evaluated on the average of 20
years after finishing treatment. 118 (92%) patients were
desensitized to grass pollen, to birch pollen (30%), cat
dander (30%) and dust mite (28%). At the time of the
study 67% reported to be asymptomatic or with greatly
improved allergy symptoms. Males had better response
to AIT than women (p=0.04). Participants with positive
family history of allergy and/or asthma in first degree
relatives also reported better response to AIT (p=0.02).
Furthermore, AIT to grass pollen and dust mite seemed
to be more effective than AIT to cat dander and birch
(p=0.04). AIT was also shown to reduce asthma.
Conclusion: AIT for 3-5 years provides significant
beneficial effect of allergy and asthma symptoms in
patients who undergo such therapy. Finally, it's findings
support the notion that AIT may reduce the risk of new
allergic manifestations.
Rikardsson SG, Löve YB, Jorgensen GH, Gislason D, Ludviksson BR.
Allergen immunotherapy in lceland 1977-2006. Icel Med J 2010; 96:463-8.
Keywords: allergy, allergen immunotherapy, asthma, long term effect.
Correspondance: Björn Rúnar Lúðvíksson, bjornlud<Slandspitali.is
468 LÆKNAblaðií 2010/96
Barst: 9. desember 2009, - samþykkt til birtingar: 15. júní 2010
Hagsmunatengsl: Engin